SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 27, 2016

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

	Nevada	000-53605	26-1265381
	(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
	incorporation)		Identification No.)
400 Water Street, Suite 200, Rochester, MI		er, MI	48307
(Address of principal executive offices)		ices)	(Zip Code)
Registrant's telephone number, including area code: <u>248.651.6568</u>			
(Former name or former address, if changed since last report)			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		

SECTION 8 – Other Events

Item 8.01 Other Events

On May 27, 2016, we settled an action pending in the United States District Court in the Eastern District of Michigan involving our former officer and director, Shadron Stastney. This settles an action that was initiated in the fourth quarter of 2014. For a complete release of claims and dismissal of the action, we agreed to pay Mr. Stastney \$50,000 and to issue him 100,000 shares of our common stock. We further agreed to register 133,333 of his existing shares with the Securities and Exchange Commission on Form S-1 by June 30, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OptimizeRx Corporation

/s/ Doug Baker
Doug Baker
Chief Financial Officer

Date: June 1, 2016